SCHEMBL2325802

SCHEMBL2325802

CC(=O)c1ccc(-c2sc(NC(=O)NCCc3cn(CCF)cn3)nc2C)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 17/20 0.56
PIK3CA P42336 13/20 0.56
PIK3CD O00329 10/20 0.56
PIK3CB P42338 9/20 0.56
PI4KB Q9UBF8 3/20 0.56
PRKDC P78527 2/20 0.46
CYP2C9 P11712 1/20 0.46
KCNH2 Q12809 1/20 0.46
CLK2 P49760 2/20 0.41
CLK1 P49759 1/20 0.41
DYRK3 O43781 1/20 0.39
MAP4K4 O95819 1/20 0.39
DYRK1A Q13627 1/20 0.39
MINK1 Q8N4C8 1/20 0.39
CLK4 Q9HAZ1 1/20 0.39
NTRK1 P04629 1/20 0.37
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2953327 0.93 PIK3CG (0.49) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2954498 0.92 PIK3CG (0.48) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2327763 0.92 PIK3CG (0.48) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2961266 0.90 PIK3CG (0.47) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL12991160 0.90 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2955998 0.89 PIK3CG (0.46) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2359821 0.88 PIK3CG (0.46) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2958630 0.84 PIK3CG (0.58) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2260708 0.83 PIK3CG (0.63) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB
SCHEMBL2359296 0.82 PIK3CG (0.44) PIK3CGPIK3CAPIK3CDPIK3CBPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357179-A1 Thiazol-2-yl organic compounds Novartis AG (CH) 2011-08-17 EP claimed
US-7754746-B2 Organic compounds NOVARTIS AG (CH) 2010-07-13 US claimed
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma NOVARTIS AG 2008-12-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319033-A1 3-{3-[5-(4-acetylphenyl)-4-methylthiazol-2-yl]-ureido}-N-tert-butylpropionamide, exhibiting phosphatidylinositol 3-kinase inhibitory activity and used for treating respiratory system disorders, such as asthma AKT3, PIK3R3, PIK3CD PIK3CG 10/4885PIK3CA 4/4885PIK3CD 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.